Private Sector Investing More Than Previously Thought In Efforts To Address Antimicrobial Resistance, Report Shows

Devex: Funding outlook shifts in fight against antimicrobial resistance
“Twenty-two research-based biopharmaceutical companies — including AstraZeneca, GlaxoSmithKline, and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR…” (Anders, 1/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.